Gossamer Bio (GOSS) EBIT: 2022-2025
Historic EBIT for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to -$49.1 million.
- Gossamer Bio's EBIT fell 44.80% to -$49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$160.8 million, marking a year-over-year decrease of 120.85%. This contributed to the annual value of -$59.9 million for FY2024, which is 67.39% up from last year.
- Latest data reveals that Gossamer Bio reported EBIT of -$49.1 million as of Q3 2025, which was down 26.70% from -$38.8 million recorded in Q2 2025.
- Gossamer Bio's EBIT's 5-year high stood at $52.1 million during Q2 2024, with a 5-year trough of -$56.0 million in Q3 2022.
- In the last 3 years, Gossamer Bio's EBIT had a median value of -$40.5 million in 2023 and averaged -$33.5 million.
- Per our database at Business Quant, Gossamer Bio's EBIT spiked by 212.50% in 2024 and then crashed by 174.42% in 2025.
- Quarterly analysis of 4 years shows Gossamer Bio's EBIT stood at -$54.4 million in 2022, then climbed by 9.81% to -$49.0 million in 2023, then increased by 26.31% to -$36.1 million in 2024, then tumbled by 44.80% to -$49.1 million in 2025.
- Its last three reported values are -$49.1 million in Q3 2025, -$38.8 million for Q2 2025, and -$36.8 million during Q1 2025.